Stock comparison
Eli Lilly
Novo Nordisk A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
NVO
Novo Nordisk A/S
Market cap
$199.21B
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LLY | NVO | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 65B | LLY |
| Benjamin Graham | 86A | 61C | LLY |
| Philip Fisher | 86A | 73B | LLY |
| Peter Lynch | 74B | 57C | LLY |
| Joel Greenblatt | 78C | 56C | LLY |
| Charlie Munger | 85A | 76B | LLY |
| Terry Smith | 77C | 72C | LLY |
Side-by-side metrics
| Metric | LLY | NVO |
|---|---|---|
| Market cap | $1T | $199.21B |
| P/E (TTM) | 36.6x | 10.4x |
| EV/EBIT | 34.1x | 10.9x |
| ROIC (TTM) | 32.06% | 32.2% |
| Gross margin | 83.51% | 81.85% |
| Net margin | 34.98% | 37.2% |
| Revenue CAGR 5y | 23.17% | 21.72% |
| EPS CAGR 5y | 40.81% | 22.03% |
| Debt / Equity | 1.4x | 0.7x |
| Dividend yield | 0.62% | 4.09% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LLY leads on
- Market cap$1Tvs $199.21B+80%
- EPS CAGR 5y40.81%vs 22.03%+46%
- Revenue CAGR 5y23.17%vs 21.72%+6%
NVO leads on
- Dividend yield4.09%vs 0.62%+85%
- P/E (TTM)10.4xvs 36.6x+72%
- EV/EBIT10.9xvs 34.1x+68%
- Debt / Equity0.7xvs 1.4x+48%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.